Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Go back to Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026| (NASDAQ: VIR) | Delayed: 8.61 +0.09 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.52 | 52 Week High | $ | |||
| Open | $8.68 | 52 Week Low | $ | |||
| Day High | $8.86 | P/E | N/A | |||
| Day Low | $8.52 | EPS | $ | |||
| Volume | 1,177,220 | |||||
